// App-Quantinova.ai

BSH2020‐PO‐117 : Panobinostat in combination with bortezomib and dexamethasone for heavily pre‐treated myeloma: a UK real‐world multi‐centre cohort

Researchers

Presenter

  • N. Maouche

Principal Investigators

  • B. Kishore

  • Z. Bhatti

  • B. Supratik

  • F. Karim

  • S. Sundararaman

  • F. Collings

  • B. Tseu

  • H. Leary

  • N. Ryman

  • U. Reddy

  • G. Vallance

  • J. Kothari

  • F. Djebbari

  • K. Ramasamy

Medical Centers

  • Dept of Haematology, Oxford University Hospitals NHS Foundation Trust

  • Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

  • Department of Haematology, The Royal Wolverhampton NHS Trust, Wolverhampton

  • Haematology, Great Western Hospital Foundation Trust, Swindon

  • Department of Haematology, Buckinghamshire Healthcare NHS Trust, Bucks

  • Department of Haematology, Milton Keynes University Hospital NHS Foundation Trust, Milton Keynes

  • Department of Haematology, Hampshire Hospitals NHS Foundation Trust, Basingstoke, UK

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Cardiovascular (CVS)

  • Oncology (ONC)

  • Peripheral Nervous System

Disease

  • Multiple Myeloma

  • Peripheral neuropathy

  • Thrombocytopenia

  • Congestive heart failure

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Pomalidomide

  • CC-4047

  • Panobinostat

  • daratumumab Intravenous

  • Bortezomib

Outcome

  • N/A

Study Design

  • Multicenteric

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved